Relapsed or refractory classical Hodgkin lymphoma - with Dr Robin Gasiorowski. EHA 2020

Описание: KEYNOTE 204 study – relapsed or refractory classical Hodgkin lymphoma
European Hematology Association (EHA) congress

Dr Robin Gasiorowski
Concord Hospital, Sydney

Dr Robin Gasiorowski from Concord Hospital spoke to Donna Gairns, National Nurse Director with Lymphoma Australia about a study that was presented during the recent European Hematology Association (EHA) Congress, held in June 2020.

Dr Robin Gasiorowski is one of the leading investigators in Australia for the international clinical trial that has been named KEYNOTE 204. It is a randomised phase 3 trial that compared the overall outcomes and the side effect profile of two therapies that are currently approved in the relapsed or refractory classical Hodgkin lymphoma group: pembrolizumab and brentuximab vedotin.

The results found that the patients both responded significantly better, but also found that the side effects were less in the group who received pembrolizumab compared to the group who received brentuximab vedotin.

Through this study, it shows that pembrolizumab is the preferred new standard of care for patients with relapsed or refractory classical Hodgkin lymphoma.

Dr Gasiorowski also discussed a study that looked at PET negative early-stage unfavourable Hodgkin lymphoma who had good results when they received a higher dose chemotherapy regimen for fewer cycles, that omitted the need for radiotherapy to consolidate after treatment. This is good for young patients who receive less toxic therapy and experience less late effects from treatment. This will provide clinicians with more information to best inform treatment.

For a full list of abstracts that were discussed, visit the Lymphoma Australia website:
http://www.lymphoma.org.au/news/141/c...

For support, contact the Lymphoma Nurse Support Line - 1800 953 081 or email [email protected]